Tanes I. Lima

May 17, 2023 | science.org | Ernest Moles |Sean Anderson |Tanes I. Lima |Yuanyuan Wang

(0)eLetters eLetters is a forum for ongoing peer review. eLetters are not edited, proofread, or indexed, but they are screened. eLetters should provide substantive and scholarly commentary on the article. Embedded figures cannot be submitted, and we discourage the use of figures within eLetters in general. If a figure is essential, please include a link to the figure within the text of the eLetter. Please read our Terms of Service before submitting an eLetter. Log In to Submit a Response

May 17, 2023 | science.org | Ernest Moles |Sean Anderson |Tanes I. Lima |Saravanan Raju

AbstractChikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that causes epidemics of acute and chronic musculoskeletal disease. Here, we analyzed the human B cell response to a CHIKV-like particle–adjuvanted vaccine (PXVX0317) from samples obtained from a phase 2 clinical trial in humans (NCT03483961). Immunization with PXVX0317 induced high levels of neutralizing antibody in serum against CHIKV and circulating antigen–specific B cells up to 6 months after immunization.

May 10, 2023 | science.org | Ernest Moles |Sean Anderson |Tanes I. Lima |Wei Shi

AbstractCheckpoint immunotherapy has yielded meaningful responses across many cancers but has shown modest efficacy in advanced prostate cancer. B7 homolog 3 protein (B7-H3/CD276) is an immune checkpoint molecule and has emerged as a promising therapeutic target. However, much remains to be understood regarding B7-H3’s role in cancer progression, predictive biomarkers for B7-H3–targeted therapy, and combinatorial strategies.